HOME >> MEDICINE >> NEWS
Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research

La Jolla, Calif. - Salk scientist Dr. Tony Hunter is the recipient of the 2006 Pasarow Award in Cancer Research for his key discoveries of the chemical switch that turns healthy cells into cancer cells.

The annual Pasarow Medical Research Awards, presented by the Los Angeles-based Robert J. and Claire Pasarow Foundation, are designed to recognize distinguished accomplishments in basic and/or clinical research while increasing public awareness of vital areas of investigation.

Also receiving Pasarow Awards are Daniel Steinberg, M.D., Ph.D., FAHA Professor and Endowed Chair at the University of California, San Diego, for cardiovascular research, and Howard Hughes Medical Investigator Dr. Huda Y. Zoghbi, a professor at the Baylor College of Medicine, Houston, for research in the field of neuropsychiatry

In 1979, Dr. Hunter, an American Cancer Society professor in the Salks Molecular and Cell Biology Laboratory, discovered that a biological process called tyrosine phosphorylation is a chemical on-off switch that can trigger the uncontrolled division of cells -- the hallmark of many cancers. Discovery of this important signaling mechanism, which proved to be the underlying cause of many types of human cancer, revolutionized cancer research and, ultimately, led to the development of several innovative cancer therapies (e.g., Gleevec(r), Iressa(r) and Tarceva(r)), as researchers found ways to inhibit the special proteins called tyrosine kinases that are responsible for tyrosine phosphorylation.

Phosphorylation - the addition of a tiny phosphate ion to a large protein molecule - is a common way in which the body turns on or off proteins such as enzymes. Thus, phosphorylation of proteins in cells, which is often triggered by external stimuli, acts as a signaling mechanism for cells to respond to their environment, and in particular to respond to factors that promote cell proliferation. Dr. Hunter discovered that phosphorylation of
'"/>

Contact: Gina Kirchweger
Kirchweger@salk.edu
858-453-4100 x1340
Salk Institute
4-Jun-2007


Page: 1 2

Related medicine news :

1. Idursulfase is effective treatment for Hunter syndrome, clinical trial concludes
2. Indiana University Imaging Center receives $6M grant for kidney research
3. FPG receives $8 million for autism research
4. Boston University School of Medicine faculty member receives honorary degree from alma mater
5. UCLA Stroke Center receives American Stroke Associations Initial Achievement Award
6. San Francisco VA researcher receives top Veterans Affairs award
7. Ronald W. Busuttil receives American Surgical Associations highest honor
8. Menzies School of Health Research receives $5.3 million in Federal Budget
9. Who receives a kidney transplant first?
10. UD receives $1.9 million for new spintronics center
11. Margaret Foti receives AACR Award for Leadership and Extraordinary Achievements in Cancer Research

Post Your Comments:
(Date:6/19/2013)... (PRWEB) June 19, 2013 Kansas City will host ... Main Street Day . A section of Main Street in ... during the afternoon of the event. The Main Street Corridor ... event, which will help Kansas City join the ranks of dozens ... as a tool to foster community vibrancy and active lifestyles. , ...
(Date:6/19/2013)... In 2011, the value of the ... Generic drugs form the largest sector, accounting for nearly ... industry is a significant contributor to the local economy; ... Approximately 50% of the total domestic chemical industry output ... Galenika and Zdravlje Actavis are key participants in the ...
(Date:6/19/2013)... 19, 2013 Elsevier, a world-leading provider of ... announced today the publication of the National Osteoporosis ... management of osteoporosis in postmenopausal women and older ... Published in 2009 in Maturitas , the ... update is timely with an additional focus on ...
(Date:6/19/2013)... Next Thursday, June 27, 2013, ... organization, and Muzzy Lane Software , a ... the Games for Health community to their interactive ... toward students in grades 4-7 and designed to ... positive choices. The game is part of a ...
(Date:6/19/2013)... Maui'd Forever , Hawaii's premiere ... an effective and cost effective way to provide for ... up with Tom Barefoot’s Tours providing an activity agent ... Hawaii’s activities. , They have just released a new ... lowest prices on their Hawaii activities. , Maui’d ...
Breaking Medicine News(10 mins):Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2
(Date:6/19/2013)... NESS ZIONA, Israel , ... today announced that results from a phase I study ... study in advanced Parkinson,s patients, of ND0612, were presented ... Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug ... (SC) delivery patch that would maintain constant levodopa plasma ...
(Date:6/19/2013)... 19, 2013  This year alone, The Leukemia & ... projects with one goal in mind: Discovering lifesaving therapies ... Training" (TNT), a flagship LLS fundraising campaign and the ... marking its landmark 25 th anniversary. To date, ... in research to discover and deliver breakthrough cancer treatments ...
(Date:6/19/2013)... June 19, 2013   Life Technologies Corporation ... licensing agreement granting Suzhou Ribo Life Sciences (Ribo) ... therapeutics in China using ... proprietary siRNA molecules in combination with Invivofectamine® Rx ... human diseases with high unmet medical need in ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4
Cached News: